CWM
AVIR icon

CIBC World Markets’s Atea Pharmaceuticals AVIR Stock Holding History

CIBC World Markets’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-17,122
Closed -$51.2K – 1591
2025
Q1 		$51.2K Buy
+17,122
New +$53.4K ﹤0.01% 1713

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CIBC World Markets's AVIR Position: Q2 2025 in Review

CIBC World Markets sold out of Atea Pharmaceuticals (AVIR) in Q2 2025, closing a stake of 17,122 shares — an estimated $51.2K sold.

CIBC World Markets first reported a position in AVIR in Q1 2025 and held it in 1 quarter. The position peaked at $51.2K in Q1 2025. 106 funds tracked by Wall St. Rank hold AVIR as of Q2 2025.

  • CIBC World Markets reported no remaining Atea Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • CIBC World Markets sold 17,122 Atea Pharmaceuticals shares in Q2 2025, an estimated $51.2K.
  • CIBC World Markets first reported a position in Atea Pharmaceuticals in Q1 2025 and held it in 1 quarter.
  • CIBC World Markets's Atea Pharmaceuticals position peaked at $51.2K in Q1 2025.
  • 106 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2025.

Based on CIBC World Markets's 13F filing for Q2 2025, filed 14 Aug 2025.